Latest News
Ganymed Pharmaceuticals AG Announces
Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer - July 2014

Our mission

At Ganymed, we aim to revolutionize cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on cancer cells, but do not bind to healthy cells.

Due to this unmatched cancer-cell specificity, IMABs will be high-precision therapeutics that efficiently kill cancer cells without harming normal healthy tissues.

Contact information
Ganymed Pharmaceuticals AG
An der Goldgrube 12
55131 Mainz, GERMANY
+49 (0) 6131 / 1440-100
+49 (0) 6131 / 1440-114